Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Income Tax Expense · Q3 FY2026 · quarter ended Aug 2026

Income tax expense remains negative

Q3 FY2026 income tax expense was $13.61M, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $13.34M.

Context

  • Income tax expense amounted to 0.9% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $13.61M or moves back toward the trailing-twelve-month quarterly average of $3.33M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterAug 2026
$13.61M+5120.7% QoQ
Last fiscal yearNov 2025
$760K+181.5% YoY
LTMAug 2026
$13.34M+1636.3% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+181.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
760K USD
Year-over-year change
+181.5%
4-year CAGR
+55.2%

Income Tax Expense vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 income tax expense of $13.34M is the highest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of +1636.3% is the highest of 6, against a peer median of -96.5%.
  • Income tax expense amounts to 1.9% of revenue for NRIX, versus a peer median of 0.1%.
NRIX Competitors Peer median
Income Tax Expense for NRIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$13.34M +1636.3%—1.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$121K -7.6%—0.3%
KURAKura Oncology, Inc.LTM Mar 2026$79K -96.5%—0.1%
RVMDRevolution Medicines, Inc.LTM Jun 2026$0 +100.0%——
KYMRKymera Therapeutics, Inc.LTM Jun 2026$0 ——0.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
TNGXTango Therapeutics, Inc.LTM Sep 2026-$53K -149.1%-58.0%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026-$242.26M -25708.8%—80.8%
Peer median (excluding NRIX) $0-96.5%-58.0%0.1%

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Revenue29.75M38.63M76.99M54.55M83.98M
Cost of Revenue116.43M184.5M189.15M221.63M18.86M
Gross Profit(86.68M)(145.87M)(112.16M)(167.08M)65.12M
Gross Margin-291.4%-377.6%-145.7%-306.3%77.5%
Research & Development116.43M184.5M189.15M221.63M308.16M
Selling, General & Admin31.2M38M42.9M45.94M52.74M
Operating Expenses31.2M38M42.9M45.94M350.79M
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
EBITDA(110.98M)(169.55M)(130.29M)(176.87M)(244.84M)
EBITDA Margin-373.0%-438.9%-169.2%-324.2%-291.5%
Operating Income(117.89M)(183.87M)(155.06M)(213.03M)(285.67M)
Operating Margin-396.3%-476.0%-201.4%-390.5%-340.2%
Interest Income823K3.51M11.12M19.73M21.97M
Interest Expense00000
Other Income / Expenses823K3.51M11.12M19.73M21.97M
Income Before Tax(117.06M)(180.36M)(143.95M)(193.3M)(263.7M)
Pre-Tax Margin-393.5%-466.9%-187.0%-354.4%-314.0%
Income Tax Expense131K00270K760K
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Net Margin-393.9%-466.9%-187.0%-354.9%-314.9%
EPS (Basic)(2.73)(3.71)(2.65)(2.88)(3.05)
EPS (Diluted)(2.73)(3.71)(2.65)(2.88)(3.05)
Weighted Avg Shares42.9M48.61M54.34M67.12M86.67M
Weighted Avg Shares (Diluted)42.9M48.61M54.34M67.12M86.67M

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.